SCHEMBL20013155

CCCCCCCCCCCCCCCC(=O)N[C@@H](CCn1cc(C[C@H](NC(=O)CNC(=O)[C@@H]2CSCC(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CCC(N)=O)C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N(C)[C@@H](CCCC)C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CCC(=O)O)C(=O)N2)C(=O)NCC(N)=O)nn1)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 9)

	gene	UniProt	supporting neighbours	confidence
▸	CD274	Q9NZQ7	9/20	0.61

▸	PDCD1	Q15116	7/20	0.53

▸	CIB1	Q99828	2/20	0.48

▸	NECTIN4	Q96NY8	2/20	0.48

▸	TNFRSF9	Q07011	3/20	0.45

▸	EPHA2	P29317	1/20	0.45

▸	KLKB1	P03952	2/20	0.45

▸	ACE	P12821	1/20	0.44

▸	ACE2	Q9BYF1	1/20	0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL22199492	0.99	CD274 (0.62)	CD274PDCD1CIB1NECTIN4TNFRSF9
SCHEMBL20013173	0.97	CD274 (0.60)	CD274PDCD1CIB1NECTIN4TNFRSF9
SCHEMBL20013471	0.97	CD274 (0.61)	CD274PDCD1CIB1NECTIN4TNFRSF9
SCHEMBL17760972	0.96	CD274 (0.56)	CD274PDCD1CIB1NECTIN4TNFRSF9
SCHEMBL22199647	0.93	CD274 (0.55)	CD274PDCD1CIB1NECTIN4TNFRSF9
SCHEMBL20013145	0.93	CD274 (0.53)	CD274PDCD1CIB1NECTIN4TNFRSF9
SCHEMBL21908259	0.93	CD274 (0.55)	CD274PDCD1CIB1NECTIN4TNFRSF9
SCHEMBL20013481	0.91	CD274 (0.65)	CD274PDCD1CIB1NECTIN4EPHA2
SCHEMBL21908386	0.91	CD274 (0.52)	CD274PDCD1CIB1NECTIN4TNFRSF9
SCHEMBL17810866	0.90	CD274 (0.69)	CD274PDCD1CIB1NECTIN4EPHA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-10633419-B2	Immunomodulators	BRISTOL-MYERS SQUIBB COMPANY (US)	2020-04-28	—	—	US	disclosed
US-20180086793-A1	IMMUNOMODULATORS	BRISTOL MYERS SQUIBB CO (US)	2018-03-29	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-10633419-B2	Immunomodulators	CD74, ICOS, HAVCR2	CD274 36/4885PDCD1 79/4885CIB1 1031/4885
US-20180086793-A1	IMMUNOMODULATORS	CD74, ICOS, HAVCR2	CD274 36/4885PDCD1 79/4885CIB1 1031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.